NCT07178158 Enhancing Addiction Treatment Through Psychoeducation
| NCT ID | NCT07178158 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Virginia Commonwealth University |
| Condition | Substance Use Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-07-23 |
| Primary Completion | 2027-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-07-23 with a primary completion date of 2027-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Addiction is a brain disorder characterized by a broad range of both apparent and subtle cognitive impairments in attention, memory, executive functions, and decision-making. These cognitive problems are clinically significant and may contribute to poor treatment outcomes in people with Substance Use Disorders (SUDs), such as a high risk of dropout, low treatment compliance, and shorter periods of abstinence. Studies on cognitive function in SUDs reveal that chronic use of drugs and alcohol can also negatively affect another crucial component of cognition: awareness, or metacognition. Metacognition is defined as an individual's ability to perceive and understand their cognitive functions and use this understanding to regulate them. One of the key consequences of metacognitive impairments is the lack of insight in people with SUDs, which adversely affects treatment outcomes. Substance users with poor metacognition are more reluctant to initiate or continue treatment and are more likely to deny their cognitive problems. Therefore, improving metacognition may remove or reduce motivational barriers to invest time and effort in the recovery process in general, and in the brain recovery process specifically. Despite the importance of neurocognition and metacognition in the recovery process for substance users, there is a dearth of interventions designed to target these functions.
Eligibility Criteria
Inclusion Criteria: * current DSM-5 opioid and/or stimulant use disorder * currently on medication treatment for SUD * owning a smartphone with sufficient functionality to download and utilize the NIPA app. Exclusion Criteria: * current psychosis, mania, or suicidal/homicidal ideation * non-English speaking
Contact & Investigator
Jasmin Vassileva, Ph.D.
PRINCIPAL INVESTIGATOR
Virginia Commonwealth University
Frequently Asked Questions
Who can join the NCT07178158 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Substance Use Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07178158 currently recruiting?
Yes, NCT07178158 is actively recruiting participants. Contact the research team at mcleankl@vcu.edu for enrollment information.
Where is the NCT07178158 trial being conducted?
This trial is being conducted at Richmond, United States.
Who is sponsoring the NCT07178158 clinical trial?
NCT07178158 is sponsored by Virginia Commonwealth University. The principal investigator is Jasmin Vassileva, Ph.D. at Virginia Commonwealth University. The trial plans to enroll 40 participants.